Cargando…

Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey

INTRODUCTION: The diagnosis of mild cognitive impairment (MCI) refers to cognitive impairment not meeting dementia criteria. A survey among members of the American Association of Neurology (AAN) showed that MCI was considered a useful diagnosis. Recently, research criteria have been proposed for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertens, Daniela, Vos, Stephanie, Kehoe, Patrick, Wolf, Henrike, Nobili, Flavio, Mendonça, Alexandre, van Rossum, Ineke, Hort, Jacub, Molinuevo, Jose Luis, Heneka, Michael, Petersen, Ron, Scheltens, Philip, Visser, Pieter Jelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6706888/
https://www.ncbi.nlm.nih.gov/pubmed/31439020
http://dx.doi.org/10.1186/s13195-019-0525-9
_version_ 1783445770207232000
author Bertens, Daniela
Vos, Stephanie
Kehoe, Patrick
Wolf, Henrike
Nobili, Flavio
Mendonça, Alexandre
van Rossum, Ineke
Hort, Jacub
Molinuevo, Jose Luis
Heneka, Michael
Petersen, Ron
Scheltens, Philip
Visser, Pieter Jelle
author_facet Bertens, Daniela
Vos, Stephanie
Kehoe, Patrick
Wolf, Henrike
Nobili, Flavio
Mendonça, Alexandre
van Rossum, Ineke
Hort, Jacub
Molinuevo, Jose Luis
Heneka, Michael
Petersen, Ron
Scheltens, Philip
Visser, Pieter Jelle
author_sort Bertens, Daniela
collection PubMed
description INTRODUCTION: The diagnosis of mild cognitive impairment (MCI) refers to cognitive impairment not meeting dementia criteria. A survey among members of the American Association of Neurology (AAN) showed that MCI was considered a useful diagnosis. Recently, research criteria have been proposed for the diagnosis of Alzheimer’s disease (AD) in MCI based on AD biomarkers (prodromal AD/MCI due to AD). The aim of this study was to investigate the attitudes of clinicians in Europe on the clinical utility of MCI and prodromal AD/MCI due to AD criteria. We also investigated whether the prodromal AD/MCI due to AD criteria impacted management of MCI patients. METHODS: An online survey was performed in 2015 among 102 members of the European Academy of Neurology (EAN) and the European Alzheimer’s Disease Consortium (EADC). Questions were asked on how often criteria were used, how they were operationalized, how they changed patient management, and what were considered advantages and limitations of MCI and prodromal AD/MCI due to AD. The questionnaire consisted of 47 questions scored on a Likert scale. RESULTS: Almost all respondents (92%) used the MCI diagnosis in clinical practice. Over 80% of the EAN/EADC respondents found a MCI diagnosis useful because it helped to label the cognitive problem, involve patients in planning for the future, and start risk reduction activities. These findings were similar to those reported in the AAN survey. Research criteria for prodromal AD/MCI due to AD were used by 68% of the EAN/EADC respondents. The most common reasons to use the criteria were increased certainty of diagnosis (86%), increased possibilities to provide counseling (51%), facilitation of follow-up planning (48%), start of medical intervention (49%), and response to patients’ wish for a diagnosis (41%). Over 70% of the physicians considered that a diagnosis of prodromal AD/MCI due to AD had an added value over the MCI diagnosis. CONCLUSIONS: The diagnostic criteria of MCI and prodromal AD/MCI due to AD are commonly used among EAN/EADC members. The prodromal AD/MCI due to AD were considered clinically useful and impacted patient management and communication. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13195-019-0525-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6706888
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67068882019-08-28 Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey Bertens, Daniela Vos, Stephanie Kehoe, Patrick Wolf, Henrike Nobili, Flavio Mendonça, Alexandre van Rossum, Ineke Hort, Jacub Molinuevo, Jose Luis Heneka, Michael Petersen, Ron Scheltens, Philip Visser, Pieter Jelle Alzheimers Res Ther Research INTRODUCTION: The diagnosis of mild cognitive impairment (MCI) refers to cognitive impairment not meeting dementia criteria. A survey among members of the American Association of Neurology (AAN) showed that MCI was considered a useful diagnosis. Recently, research criteria have been proposed for the diagnosis of Alzheimer’s disease (AD) in MCI based on AD biomarkers (prodromal AD/MCI due to AD). The aim of this study was to investigate the attitudes of clinicians in Europe on the clinical utility of MCI and prodromal AD/MCI due to AD criteria. We also investigated whether the prodromal AD/MCI due to AD criteria impacted management of MCI patients. METHODS: An online survey was performed in 2015 among 102 members of the European Academy of Neurology (EAN) and the European Alzheimer’s Disease Consortium (EADC). Questions were asked on how often criteria were used, how they were operationalized, how they changed patient management, and what were considered advantages and limitations of MCI and prodromal AD/MCI due to AD. The questionnaire consisted of 47 questions scored on a Likert scale. RESULTS: Almost all respondents (92%) used the MCI diagnosis in clinical practice. Over 80% of the EAN/EADC respondents found a MCI diagnosis useful because it helped to label the cognitive problem, involve patients in planning for the future, and start risk reduction activities. These findings were similar to those reported in the AAN survey. Research criteria for prodromal AD/MCI due to AD were used by 68% of the EAN/EADC respondents. The most common reasons to use the criteria were increased certainty of diagnosis (86%), increased possibilities to provide counseling (51%), facilitation of follow-up planning (48%), start of medical intervention (49%), and response to patients’ wish for a diagnosis (41%). Over 70% of the physicians considered that a diagnosis of prodromal AD/MCI due to AD had an added value over the MCI diagnosis. CONCLUSIONS: The diagnostic criteria of MCI and prodromal AD/MCI due to AD are commonly used among EAN/EADC members. The prodromal AD/MCI due to AD were considered clinically useful and impacted patient management and communication. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13195-019-0525-9) contains supplementary material, which is available to authorized users. BioMed Central 2019-08-22 /pmc/articles/PMC6706888/ /pubmed/31439020 http://dx.doi.org/10.1186/s13195-019-0525-9 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Bertens, Daniela
Vos, Stephanie
Kehoe, Patrick
Wolf, Henrike
Nobili, Flavio
Mendonça, Alexandre
van Rossum, Ineke
Hort, Jacub
Molinuevo, Jose Luis
Heneka, Michael
Petersen, Ron
Scheltens, Philip
Visser, Pieter Jelle
Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey
title Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey
title_full Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey
title_fullStr Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey
title_full_unstemmed Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey
title_short Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey
title_sort use of mild cognitive impairment and prodromal ad/mci due to ad in clinical care: a european survey
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6706888/
https://www.ncbi.nlm.nih.gov/pubmed/31439020
http://dx.doi.org/10.1186/s13195-019-0525-9
work_keys_str_mv AT bertensdaniela useofmildcognitiveimpairmentandprodromaladmciduetoadinclinicalcareaeuropeansurvey
AT vosstephanie useofmildcognitiveimpairmentandprodromaladmciduetoadinclinicalcareaeuropeansurvey
AT kehoepatrick useofmildcognitiveimpairmentandprodromaladmciduetoadinclinicalcareaeuropeansurvey
AT wolfhenrike useofmildcognitiveimpairmentandprodromaladmciduetoadinclinicalcareaeuropeansurvey
AT nobiliflavio useofmildcognitiveimpairmentandprodromaladmciduetoadinclinicalcareaeuropeansurvey
AT mendoncaalexandre useofmildcognitiveimpairmentandprodromaladmciduetoadinclinicalcareaeuropeansurvey
AT vanrossumineke useofmildcognitiveimpairmentandprodromaladmciduetoadinclinicalcareaeuropeansurvey
AT hortjacub useofmildcognitiveimpairmentandprodromaladmciduetoadinclinicalcareaeuropeansurvey
AT molinuevojoseluis useofmildcognitiveimpairmentandprodromaladmciduetoadinclinicalcareaeuropeansurvey
AT henekamichael useofmildcognitiveimpairmentandprodromaladmciduetoadinclinicalcareaeuropeansurvey
AT petersenron useofmildcognitiveimpairmentandprodromaladmciduetoadinclinicalcareaeuropeansurvey
AT scheltensphilip useofmildcognitiveimpairmentandprodromaladmciduetoadinclinicalcareaeuropeansurvey
AT visserpieterjelle useofmildcognitiveimpairmentandprodromaladmciduetoadinclinicalcareaeuropeansurvey